Background: We aimed to evaluate the data of perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy regimen in locally advanced gastric cancer (LAGC) patients with real-life experience. Methods: In this retrospective study, LAGC patients who received perioperative FLOT chemotherapy regimen between 2017 and 2020 were included. The patients were grouped according to tumor regression grade (TRG): histopathological responders (complete/moderate response) and histopathological non-responders (minimal/poor response). The factors affecting TRG were evaluated and its relationship to clinical outcome was analyzed by disease-free survival (DFS) and overall survival (OS). Results: A total of 141 LAGC patients were included. Median age of patients was 62 (range: 35–75) years of whom 69.5% were men. According to TRG, 41 (29.1%) patients were histopathological responders (College of American Pathologists (CAP)-TRG 0/1). Grade, perineural and lymphovascular invasion, clinical stage, tumor markers (Carcinoembryonic antigen (CEA) and Carbohydrate antigen (CA)19-9), radiological response, and ypTNM stage were statistically significant in univariate analysis and lymphovascular invasion was detected as an independent factor in multivariate analysis for TRG. Grade 3-4 toxicities were observed in only 28 (19.9%) patients. Two years DFS and OS rates were higher in the histopathological responder group (100% and 100%) compared to the histopathological non-responder group (59% and 52.9%) (P = 0.01 and P = 0.02, respectively). Conclusion: In our study, it was found that the FLOT regimen had a favorable TRG and a safe toxicity profile in gastric cancer patients. In addition, while lymphovascular invasion could predict TRG, the survival and disease recurrence were positively affected by the favorable TRG response.
15 December 2025 in Biological Diversity and Conservation
Purpose: Colon cancer is one of the most common cancers of the digestive system and usually develops when polyps develop into cancer. Factors such as age, genetic predisposition and dietary habits increase the risk of the disease. Therefore, early diagnosis of colon cancer and development of appropriate clinical approaches are of great importance today. Sphingolipids are essential biological molecules that serve as important components of cell membranes and play important roles in various cellular processes. They are involved in various basic biological processes such as cell growth and differentiation, especially apoptosis (programmed cell death) and intracellular signaling. Sphingolipids are divided into different subgroups such as ceramide, sphingomyelin and glycosphingolipid and coordinate the design and activities of cells and play important roles in anticancer processes such as cell cycle arrest and inducing apoptosis. Dysfunction of sphingolipid metabolism plays a critical role in the development and progression of numerous cancers. Altered sphingolipid balance in cancer cells can affect the regulation of processes such as cellular growth, invasion and metastasis. In particular, changes in ceramide levels can activate cell survival pathways and cause cancer to become more aggressive. Method: In order to investigate the potential anticancer effects of ceramide inhibitor, we investigated the effects of D-e MAPP, a ceramidase inhibitor, on HT29 colon cancer cell line. For this purpose, cell viability and morphological changes after treatment were evaluated in detail. Cell viability was determined by MTT assay to determine the cytotoxic effects of treatment. Furthermore, structural and morphological changes in cells were visualized by confocal microscopy and treatment-induced cell death modes were determined by flow cytometry to obtain detailed information on cell death pathways. Findings: These methods aim to contribute to a more comprehensive understanding of the effects of ceramidase inhibitors on colon cancer cells. Conclusion: This study aims to contribute to a more comprehensive understanding of the effects of ceramidase inhibitors such as D-e-MAPP on colon cancer cells. By assessing cell viability, morphological changes and cell death pathways, this research provides valuable insights into the potential therapeutic applications of targeting sphingolipid metabolism in colon cancer treatment. Keywords: Colon cancer, sphingolipids, D-e-MAPP
The aim of this multicentre retrospective study was to compare the efficacy of adjuvant chemotherapy regimens both with and without oxaliplatin and tumor sidedness in stage IIB (pT4aN0) colon cancer patients. This study included patients with stage IIB colon cancer who underwent curative surgery and received adjuvant chemotherapy. The patients were divided into two groups (one with and one without oxaliplatin) to compare the overall survival (OS) in right- and left-sided tumors. The study population included 298 patients with stage IIB colon cancer (median age: 57) of whom 69.1% were male. Forty-four per cent of these patients (n = 131) were diagnosed with right-sided colon cancer. The median follow-up duration was 35.9 months. In the entire population, a median OS was not reached, and the five-year OS was 83%. The median disease-free survival (DFS) was 12 months. There was no significant difference in terms of the five-year OS between right- (82%) and left-sided (84%) colon tumors (p = 0.67). In addition, the five-year OS of patients treated with and without oxaliplatin were 76% and 89%, respectively, and there was no statistically significant difference (p = 0.23). The five-year OS of the patients treated with and without oxaliplatin were 83% and 96.5%, respectively, (p = 0.8) in right-sided colon tumors, while it was 75% and 93% (p = 0.06), respectively, in left-sided colon tumors. Tumor sidedness and the addition of oxaliplatin to adjuvant chemotherapy were not found to be associated with the OS in stage IIB colon cancer patients in our study. Further large prospective studies that also include MSI, RAS and BRAF status data are warranted in colon cancer patients.